IP Library Granted Patent US 7,858,784
Granted Patent B2
US 7,858,784 · App. 12/334,083 · Granted Dec 28, 2010

Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof

Assignee: Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,784
App. No.
12/334,083
Granted
Dec 28, 2010
Kind
B2
Abstract

Ligands for transition metals are disclosed herein, which may be used in various transition-metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The disclosed methods provide improvements in many features of the transition-metal-catalyzed reactions, including the range of suitable substrates, number of catalyst turnovers, reaction conditions, and efficiency. For example, improvements have been realized in transition-metal-catalyzed cross-coupling reactions.

Claims (83)

1. A ligand represented by I:

wherein

R is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH 2 ) m —R 10 ;

R 1 , R 2 , R 3 , and R 4 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ; or any two adjacent instances of R 1 , R 2 , R 3 and R 4 , taken together with the carbons to which they are bound, form a five- or six-membered substituted or unsubstituted aryl or heteroaryl ring;

provided that at least two of R 1 , R 2 , R 3 and R 4 are —OR 11 ;

R 5 , and R 9 are selected independently for each occurrence from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 7 is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , —(CH 2 ) m —R 10 , —OH, —OR 11 , —NH 2 , —NHR 11 , and —N(R 11 ) 2 ;

R 6 and R 8 are selected independently for each occurrence from the group consisting of hydrogen, lower alkyl and halogen;

or any two adjacent instances of R 5 , R 6 , R 7 , R 8 , or R 9 , taken together with the carbons to which they are bound, form a five- or six-membered substituted or unsubstituted aryl or heteroaryl ring;

R 10 represents an unsubstituted or substituted aryl, cycloalkyl, cycloalkenyl, heterocycle, or polycycle, wherein polycycle refers to two or three rings, each ring independently selected from the group consisting of cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and heterocyclyls, in which two or more carbons are shared by adjoining rings;

R 11 is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the ligand is achiral or, when chiral, is a single stereoisomer or a mixture of stereoisomers.

2. The ligand of claim 1 , wherein R 5 , R 7 and R 9 are selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 .

3. The ligand of claim 1 , wherein R is alkyl, aryl, or cycloalkyl.

4. The ligand of claim 1 , wherein R is Cy, i-Pr, C 5 H 11 , Me, Et, 1-adamantyl, t-Bu,

5. The ligand of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 )R 10 .

6. The ligand of claim 1 , wherein R 1 and R 4 are —OR 11 .

7. The ligand of claim 1 , wherein R 1 and R 4 are —OR 11 ; and R 11 is alkyl.

8. The ligand of claim 1 , wherein R 2 and R 3 are —OR 11 .

9. The ligand of claim 1 , wherein R 2 and R 3 are —OR 11 ; and R 11 is alkyl.

10. The ligand of claim 1 , wherein R 2 and R 4 are —OR 11 .

11. The ligand of claim 1 , wherein R 2 and R 4 are —OR 11 ; and R 11 is alkyl.

12. The ligand of claim 1 , wherein R 5 , R 7 and R 9 are alkyl.

13. A ligand represented by II:

wherein

R is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH 2 ) m —R 10 ;

R 2 and R 3 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 1 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 ) m —R 11 ; or any two adjacent instances of R 2 and R 3 , taken together with the carbons to which they are bound, form a five or six-membered, substituted or unsubstituted, aryl or heteroaryl ring;

R 5 , R 7 and R 9 are selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 6 and R 8 are selected independently for each occurrence from the group consisting of hydrogen, lower alkyl and halogen;

R 10 represents an unsubstituted or substituted aryl, cycloalkyl, cycloalkenyl, heterocycle, or polycycle, wherein polycycle refers to two or three rings, each ring independently selected from the group consisting of cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and heterocyclyls, in which two or more carbons are shared by adjoining rings;

R 11 is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the ligand is achiral or, when chiral, is a single stereoisomer or a mixture of stereoisomers.

14. The ligand of claim 13 , wherein R is alkyl, aryl, or cycloalkyl.

15. The ligand of claim 13 , wherein R is Cy, i-Pr, C 5 H 11 , Me, Et, 1-adamantyl, t-Bu,

16. The ligand of claim 13 , wherein R 11 is alkyl.

17. The ligand of claim 13 , wherein R 2 and R 3 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , Si(R 11 ) 3 , and —(CH 2 ) m —R 10 .

18. The ligand of claim 13 , wherein R 2 and R 3 are —OR 11 .

19. The ligand of claim 13 , wherein R 2 and R 3 are —OR 11 ; and R 11 is alkyl.

20. The ligand of claim 13 , wherein R 2 and R 3 are alkyl.

21. The ligand of claim 13 , wherein R 5 , R 7 and R 9 are alkyl.

22. A ligand represented by III:

wherein

R is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH 2 ) m —R 10 ;

R 1 and R 4 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 5 , R 7 and R 9 are selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 6 and R 8 are selected independently for each occurrence from the group consisting of hydrogen, lower alkyl and halogen;

R 10 represents an unsubstituted or substituted aryl, cycloalkyl, cycloalkenyl, heterocycle, or polycycle, wherein polycycle refers to two or three rings, each ring independently selected from the group consisting of cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and heterocyclyls, in which two or more carbons are shared by adjoining rings;

R 11 is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the ligand, when chiral, is a mixture of stereoisomers or a single enantiomer.

23. The ligand of claim 22 , wherein R is alkyl, aryl, or cycloalkyl.

24. The ligand of claim 22 , wherein R is Cy, i-Pr, C 5 H 11 , Me, Et, 1-adamantyl, t-Bu,

25. The ligand of claim 22 , wherein R 11 is alkyl.

26. The ligand of claim 22 , wherein R 1 and R 4 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 .

27. The ligand of claim 22 , wherein R 1 and R 4 are —OR 11 .

28. The ligand of claim 22 , wherein R 1 and R 4 are —OR 11 ; and R 11 is alkyl.

29. The ligand of claim 22 , wherein R 1 and R 4 are alkyl.

30. The ligand of claim 22 , wherein R 5 , R 7 and R 9 are alkyl.

31. A ligand represented by IV:

wherein

R is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH 2 ) m —R 10 ;

R 1 and R 3 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 5 , R 7 and R 9 are selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —Si(R 11 ) 3 , and —(CH 2 ) m —R 10 ;

R 6 and R 8 are selected independently for each occurrence from the group consisting of hydrogen, lower alkyl and halogen;

R 10 represents an unsubstituted or substituted aryl, cycloalkyl, cycloalkenyl, heterocycle, or polycycle, wherein polycycle refers to two or three rings, each ring independently selected from the group consisting of cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and heterocyclyls, in which two or more carbons are shared by adjoining rings;

R 11 is selected independently for each occurrence from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the ligand, when chiral, is a mixture of stereoisomers or a single enantiomer.

32. The ligand of claim 31 , wherein R is alkyl, aryl, or cycloalkyl.

33. The ligand of claim 31 , wherein R is Cy, i-Pr, C 5 H 11 , Me, Et, 1-adamantyl, t-Bu,

34. The ligand of claim 31 , wherein R 11 is alkyl.

35. The ligand of claim 31 , wherein R 1 and R 3 are selected independently for each occurrence from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 11 , —N(R 11 ) 2 , —Si(R 11 ) 3 , and —(CH 2 )R 10 .

36. The ligand of claim 31 , wherein R 1 and R 3 are —OR 11 .

37. The ligand of claim 31 , wherein R 1 and R 3 are —OR 11 ; and R 11 is alkyl.

38. The ligand of claim 31 , wherein R 1 and R 3 are alkyl.

39. The ligand of claim 31 , wherein R 5 , R 7 and R 9 are alkyl.

40. The ligand of claim 1 , wherein said ligand is selected from the group consisting of:

wherein R is selected independently for each occurrence from the group consisting of alkyl, aryl, and cycloalkyl.

41. The ligand of claim 40 , wherein R is Cy, i-Pr, C 5 H 11 , Me, Et, 1-adamantyl, t-Bu,

42. The ligand of claim 40 , wherein said ligand is represented by

wherein R is Cy or t-Bu.

Assignments (4)
CONFIRMATORY LICENSE Recorded Apr 13, 2010
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024223/0128 →
CONFIRMATORY LICENSE Recorded Apr 6, 2010
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024190/0722 →
CONFIRMATORY LICENSE Recorded Mar 25, 2010
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024136/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2009
From: BUCHWALD, STEPHEN L.; FORS, BRETT P.; SURRY, DAVID S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 022684/0448 →
Continuity (3)
Provisional Application 6101317400 · Dec 12, 2007
Provisional Application 6108736800 · Aug 8, 2008
Related Publication 20090221820A1 · Sep 3, 2009